TP53 and cancer: The current study has provided further support that the combination of modulating the proinflammatory state via immunotherapeutic agents [37] with expanding pharmacologic manipulation to address undruggable molecular cancer targets may lead to novel and effective approaches to the treatment of KRAS+/TP53+ mutant advanced cancer.